Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Cyclin G associated kinase (GAK) emerged as a promising drug target for the treatment of viral infections. However, no potent and selective GAK inhibitors have been reported in the literature to date. This paper describes the discovery of isothiazolo[5,4-b]pyridines as selective GAK inhibitors, with the most potent congeners displaying low nanomolar binding affinity for GAK. Cocrystallization experiments revealed that these compounds behaved as classic type I ATP-competitive kinase inhibitors. In addition, we have demonstrated that these compounds exhibit a potent activity against hepatitis C virus (HCV) by inhibiting two temporally distinct steps in the HCV life cycle (i.e., viral entry and assembly). Hence, these GAK inhibitors represent chemical probes to study GAK function in different disease areas where GAK has been implicated (including viral infection, cancer, and Parkinson's disease).

Original publication

DOI

10.1021/jm501759m

Type

Journal article

Journal

J Med Chem

Publication Date

23/04/2015

Volume

58

Pages

3393 - 3410

Keywords

Antiviral Agents, Cell Line, Crystallography, X-Ray, Hepacivirus, Hepatitis C, Humans, Intracellular Signaling Peptides and Proteins, Models, Molecular, Protein Kinase Inhibitors, Protein-Serine-Threonine Kinases, Pyridines, Thiazoles, Virus Internalization